Kymera Therapeutics (KYMR) PT Lowered to $53 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Price: $122.51 +4.20%
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 10 | New: 6
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 10 | New: 6
Join SI Premium – FREE
Stifel analyst Bradley Canino lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $53.00 (from $55.00) while maintaining a Buy rating.
You May Also Be Interested In
- Kymera Therapeutics (KYMR) PT Raised to $146 at Morgan Stanley
- ServiceNow (NOW) PT Lowered to $150 at Truist Securities
- C.H. Robinson Worldwide (CHRW) PT Lowered to $180 at Jefferies, 'We Think the Selloff Is Overdone'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
